Novo Nordisk A/S (NYSE:NVO) Trading 1.1% Higher – Time to Buy?

Novo Nordisk A/S (NYSE:NVO) shares were up 1.1% during trading on Tuesday . The stock traded as high as $45.12 and last traded at $44.87. Approximately 21,079,233 shares were traded during mid-day trading, a decline of 5% from the average daily volume of 22,236,373 shares. The stock had previously closed at $44.39.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Company-initiated buyback: Novo Nordisk has an active share repurchase programme (part of a DKK 15bn 12?month programme) that supports EPS and signals management confidence. Novo Nordisk A/S – share repurchase programme
• Positive Sentiment: Wegovy pill early lead: Novo’s oral Wegovy has a head start versus Eli Lilly’s Foundayo, showing brisk early demand and giving Novo a distribution and branding advantage in the nascent pill market. That supports revenue upside if share gains persist. Novo Nordisk’s Wegovy pill head start forces investors to rethink Eli Lilly’s GLP-1 dominance
• Positive Sentiment: Competitor safety signal: The FDA has reported serious liver?injury cases for Eli Lilly’s Foundayo, a development that could slow uptake of a key rival and indirectly benefit Novo’s market positioning. FDA Reports Liver Failure in Patient Taking Eli Lilly’s Foundayo
• Positive Sentiment: Pipeline expansion: Novo is testing semaglutide for alcohol use disorder and started Phase 1 for LX9851 (oral obesity/metabolic candidate), which extends optionality beyond diabetes/obesity and could support longer?term growth. Novo Nordisk Extends Pipeline With Semaglutide Alcohol Study And LX9851 Trial
• Positive Sentiment: Bullish analyst view: Some investors/analysts frame NVO as a buy into potential Q1 beats and strategic pricing moves (including steep Wegovy discounts) aimed at expanding addressable market despite near?term margin pressure. Novo Nordisk: A Generational Buying Opportunity Ahead Of Q1 Earnings
• Neutral Sentiment: Earnings / guidance focus: Pre?Q1 commentary emphasizes strong GLP?1 demand and the Wegovy pill rollout but flags pricing pressure and guidance clarity as key near?term drivers for the stock. Investors should watch Q1 results and management commentary. Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
• Negative Sentiment: Price?war risk: Reuters highlights that rising prescriptions may be offset by an intensifying price war with Eli Lilly — a scenario that could compress revenue and margins if lower prices become entrenched. Novo Nordisk’s weight-loss pill boom faces price war test
• Negative Sentiment: Sector risk: A Deloitte/industry discussion warns of a “bubble effect” from GLP?1–driven growth, underscoring macro/valuation risks across pharma that could weigh on sentiment if momentum fades. ‘Bubble effect’: Weight loss drug fueled growth is putting the pharma sector at risk, report finds

Wall Street Analysts Forecast Growth

Several research analysts recently commented on NVO shares. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Morgan Stanley raised shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price objective for the company in a report on Tuesday, March 3rd. Deutsche Bank Aktiengesellschaft downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Nordea Equity Research downgraded shares of Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. Finally, Sanford C. Bernstein started coverage on shares of Novo Nordisk A/S in a report on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 price objective for the company. Four analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Stock Performance

The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $200.34 billion, a P/E ratio of 12.93, a P/E/G ratio of 10.42 and a beta of 0.77. The company’s fifty day simple moving average is $38.50 and its 200 day simple moving average is $47.19.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The company had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.34 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently disclosed a dividend, which was paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th were issued a dividend of $1.2751 per share. This represents a dividend yield of 723.0%. The ex-dividend date of this dividend was Monday, March 30th. Novo Nordisk A/S’s payout ratio is currently 50.14%.

Institutional Trading of Novo Nordisk A/S

A number of hedge funds have recently made changes to their positions in the stock. Quotient Wealth Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 2.0% during the 4th quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock worth $463,000 after acquiring an additional 177 shares during the last quarter. Certuity LLC lifted its holdings in shares of Novo Nordisk A/S by 3.6% during the 4th quarter. Certuity LLC now owns 5,052 shares of the company’s stock worth $257,000 after acquiring an additional 177 shares during the last quarter. Oakworth Capital Inc. lifted its holdings in shares of Novo Nordisk A/S by 41.6% during the 4th quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock worth $31,000 after acquiring an additional 182 shares during the last quarter. True North Advisors LLC lifted its holdings in shares of Novo Nordisk A/S by 3.9% during the 4th quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock worth $270,000 after acquiring an additional 199 shares during the last quarter. Finally, SeaBridge Investment Advisors LLC lifted its holdings in shares of Novo Nordisk A/S by 5.7% during the 3rd quarter. SeaBridge Investment Advisors LLC now owns 3,735 shares of the company’s stock worth $207,000 after acquiring an additional 200 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.